Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter


Cytomedix says proposed National Coverage Determination memo by CMS includes proposal through CED for all three major wound categories; conference call May 10 (CMXI)

Cytomedix, Inc. (CMXI.OB) is a biotechnology company developing advanced tissue regeneration technologies. Its primary focus is on commercializing autologous cell based therapies that facilitate the body’s natural healing processes for enhanced healing and tissue repair.  Its commercial portfolio is based on autologous platelet rich plasma (“PRP”) platform technology, and includes the Angel® Whole Blood Separation System (“Angel®”) and the AutoloGelTM System (“AutoloGel”). 

The company has said that "the Centers for Medicare & Medicaid Services issued a proposed National Coverage Determination memo for autologous blood-derived products for chronic non-healing wounds. In its decision memo CMS has proposed coverage through its Coverage with Evidence Development program for all three major wound categories: diabetic, venous and pressure wounds."

In the CED process, CMS provides payment for items and services while generating additional clinical data to demonstrate their impact on health outcomes. Cytomedix says that the proposed decision by CMS bodes well for its ongoing discussions with a top 20 global pharmaceutical company for an exclusive U.S. supply and distribution agreement for AutoloGel in wound care.

A Company conference call was held 10-May at 9:00 ET to discuss the proposed NCD and the CED initiatives. A replay of the conference call will be available beginning two hours after its completion through May 17, 2012 by dialing 888-286-8010 (domestic) or 617-801-6888 international) and entering passcode 61561051. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.cytomedix.com.

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV (GILD) | Main | Aastrom Biosciences Announces First Patient Enrolled in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T (ASTM) »